Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Frontiers of Medicine ; (4): 227-239, 2022.
Article in English | WPRIM | ID: wpr-929199

ABSTRACT

Chronic stress impairs radial neural stem cell (rNSC) differentiation and adult hippocampal neurogenesis (AHN), whereas promoting AHN can increase stress resilience against depression. Therefore, investigating the mechanism of neural differentiation and AHN is of great importance for developing antidepressant drugs. The nonpsychoactive phytocannabinoid cannabidiol (CBD) has been shown to be effective against depression. However, whether CBD can modulate rNSC differentiation and hippocampal neurogenesis is unknown. Here, by using the chronic restraint stress (CRS) mouse model, we showed that hippocampal rNSCs mostly differentiated into astrocytes under stress conditions. Moreover, transcriptome analysis revealed that the FoxO signaling pathway was involved in the regulation of this process. The administration of CBD rescued depressive-like symptoms in CRS mice and prevented rNSCs overactivation and differentiation into astrocyte, which was partly mediated by the modulation of the FoxO signaling pathway. These results revealed a previously unknown neural mechanism for neural differentiation and AHN in depression and provided mechanistic insights into the antidepressive effects of CBD.


Subject(s)
Animals , Humans , Mice , Cannabidiol/pharmacology , Cell Differentiation , Depression/prevention & control , Hippocampus/metabolism , Neural Stem Cells , Neurogenesis/physiology
3.
Arch. argent. pediatr ; 118(1): 64-67, 2020-02-00.
Article in English, Spanish | LILACS, BINACIS | ID: biblio-1095682

ABSTRACT

En los últimos años, se ha observado un incremento significativo en el interés por la prescripción del cannabis medicinal. En el siguiente artículo, se informa acerca de la escasa base científica que avala la prescripción de estos compuestos en un listado amplio y diverso de patologías médicas. Se considera fundamental que cualquier sustancia que vaya a ser utilizada en humanos siga un protocolo de aprobación estricto y científico, que pueda desligarse de modas o de resultados individuales. Es necesario que, antes de la prescripción de una droga en personas, deba tenerse un panorama claro de cuáles son los usos del compuesto en cuestión, pero, sobre todo, de su seguridad, que es prácticamente desconocida en el cannabis medicinal.


In recent years, the interest in medical cannabis prescription has increased significantly. This article provides information about the little scientific basis supporting the prescription of these products for a wide and diverse range of medical conditions. It is critical for any substance to be used in human beings to follow a strict scientific approval protocol, detached from any trend or individual outcome. Before prescribing any drug to human beings, it is necessary to have a clear picture of its uses, especially its safety, which is practically unknown in the case of medical cannabis.


Subject(s)
Humans , Cannabidiol/adverse effects , Cannabidiol/therapeutic use , Medical Marijuana/adverse effects , Medical Marijuana/therapeutic use , Safety , Dronabinol/therapeutic use , Cannabidiol/pharmacology , Compassionate Use Trials , Legislation, Drug
4.
Evid. actual. práct. ambul ; 22(1): e001119, abr. 2019. ilus, tab.
Article in Spanish | LILACS | ID: biblio-1014994

ABSTRACT

Esta revisión analiza la situación actual de la utilización del como herramienta terapéutica dentro del ámbito de la salud en Argentina, haciendo referencia a los distintos actores involucrados y dilemas futuros que pueden presentarse. Paracomprender en su totalidad el marco social, cultural e histórico, se desarrollan distintos aspectos, como la descripción química y biológica del , evolución del consumo a través de la historia, las repercusiones del consumo y las distintas aplicaciones que tiene en el campo de la medicina. También se describen las diferentes realidades que hay en el mundo, así como las legislaciones de otros países y la comparación de estas con la que tenemos en nuestro país. Finalmente se mencionan los desafíos pendientes y sus posibles abordajes.(AU)


This review analyzes the current situation of the use of cannabis as a therapeutic tool in the field of health in Argentina,referring to the different actors involved and future dilemmas that may arise. To fully understand the social, cultural andhistorical framework, different aspects can be defined, such as the chemical and biological description of cannabis, theevolution of consumption throughout history, the repercussions of recreational consumption and the different applicationsthat it has on the medical field. It also describes the different realities that exist in the world, as well as the laws of othercountries and the comparison of these with the one we have in our country. Finally, the pending challenges and theirpossible approaches, are mentioned.(AU)


Subject(s)
Humans , Male , Female , History, Medieval , History, 20th Century , Medical Marijuana/therapeutic use , Marijuana Use/legislation & jurisprudence , Marijuana Use/trends , Argentina , Dronabinol/adverse effects , Dronabinol/pharmacology , Cannabidiol/adverse effects , Cannabidiol/pharmacology , Cannabinoids/classification , Cannabis/classification , Cannabis/chemistry , Illicit Drugs , Public Health/trends , Marijuana Use/history , Marijuana Use/therapy
5.
Rev. bras. ter. intensiva ; 27(4): 383-389, out.-dez. 2015. graf
Article in English | LILACS | ID: lil-770045

ABSTRACT

RESUMO Objetivo: Investigar os efeitos da administração de canabidiol em um modelo de isquemia/reperfusão renal em animais. Métodos: Foi induzida uma lesão renal, por meio de 45 minutos de isquemia renal seguida por reperfusão. Administrou-se canabidiol (5mg/kg) imediatamente após a reperfusão. Resultados: A isquemia/reperfusão aumentou os níveis de interleucina 1 e fator de necrose tumoral, o que foi atenuado pelo tratamento com canabidiol. Além disso, o canabidiol foi capaz de diminuir o dano oxidativo de lipídios e proteínas, mas não os níveis de nitrito/nitrato. A lesão renal após isquemia/reperfusão pareceu ser independente da expressão dos receptores canabidiol-1 e canabidiol-2, já que não houve aumento significante desses receptores após a reperfusão. Conclusão: O tratamento com canabidiol teve um efeito protetor contra a inflamação e o dano oxidativo em um modelo de isquemia/reperfusão renal. Esses efeitos parecem não ocorrer via ativação dos receptores canabidiol-1/canabidiol-2.


ABSTRACT Objective: This work aimed to investigate the effects of the administration of cannabidiol in a kidney ischemia/reperfusion animal model. Methods: Kidney injury was induced by 45 minutes of renal ischemia followed by reperfusion. Cannabidiol (5mg/kg) was administered immediately after reperfusion. Results: Ischemia/reperfusion increased the IL-1 and TNF levels, and these levels were attenuated by cannabidiol treatment. Additionally, cannabidiol was able to decrease lipid and protein oxidative damage, but not the nitrite/nitrate levels. Kidney injury after ischemia/reperfusion seemed to be independent of the cannabidiol receptor 1 and cannabidiol receptor 2 (CB1 and CB2) expression levels, as there was no significant increase in these receptors after reperfusion. Conclusion: The cannabidiol treatment had a protective effect against inflammation and oxidative damage in the kidney ischemia/reperfusion model. These effects seemed to be independent of CB1/CB2 receptor activation.


Subject(s)
Animals , Male , Rats , Cannabidiol/pharmacology , Reperfusion Injury/drug therapy , Inflammation/drug therapy , Kidney Diseases/drug therapy , Reperfusion Injury/pathology , Interleukin-1/metabolism , Tumor Necrosis Factor-alpha/metabolism , Rats, Wistar , Oxidative Stress/drug effects , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/metabolism , Disease Models, Animal , Inflammation/pathology , Kidney Diseases/pathology
6.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;26(2): 213-7, Feb. 1993. graf
Article in English | LILACS | ID: lil-148688

ABSTRACT

In the present study, we investigated the effects of cannabidiol (CBD) on plasma prolactin, growth hormone and cortisol of 11 normal volunteers who received placebo or CBD at the doses of 300 mg (N = 7) or 600 mg (N = 4), po, in a double-blind manner during two experimental sessions separated by an interval of at least one week. The sessions were held in the morning and consisted of blood collection and application of self-evaluation scales before and after drug injection (-35 to 180 min). Hormonal measurements were performed by radioimmunoassay. Basal prolactin (11.5 +/- 4.3 ng/ml) and growth hormone (1.5 +/- 0.7 ng/ml) levels were unchanged after placebo and CBD. In contrast, plasma cortisol levels decreased significantly during the placebo sessions (basal measurement = 11.0 +/- 3.7 micrograms/dl; 120 min after placebo = 7.1 +/- 3.9 micrograms/dl), in agreement with the normal circadian rhythm of this hormone. This decrease in cortisol levels was significantly attenuated after CBD (basal measurement = 10.5 +/- 4.9 micrograms/dl; 120 min after 300 mg CBD = 9.9 +/- 6.2 micrograms/dl; 120 min after 600 mg CBD = 11.6 +/- 11.6 micrograms/dl). CBD was also found to have a sedative effect as determined by the self-evaluation scales. The present results suggest that CBD interferes with cortisol secretion


Subject(s)
Humans , Male , Adult , Cannabidiol/pharmacology , Growth Hormone/blood , Hydrocortisone/blood , Prolactin/blood , Double-Blind Method , Radioimmunoassay , Time Factors
7.
Rev. bras. genét ; 12(3): 613-23, Sept. 1989. tab, ilus
Article in English | LILACS | ID: lil-75428

ABSTRACT

Investigou-se o efeito in vitro do canabidiol (CBD) sobre o índice mitótico e a frequência de células com aberraçöes cromossômicas numéricas e/ou estruturais, em culturas de linfócitos humanos. Em uma primeira fase o CBD foi dissolvido em álcool etílico absoluto (0,01 ml/ml de meio) nas concentraçöes de 0,001, 0,01 0,1, e 10,0 microng de CBD/ml de meio e, na segunda fase, o etanol foi evaporado antes de ser adicionado o meio de cultura. O efeito clastogênico do CBD foi maior quando associado ao álcool. A açäo do etanol foi predominantemente anti-mitogênica enquanto o CBD teve efeito mais nítido sobre a produçäo de células com aberraçöes cromossômicas. Após a evaporaçäo do etanol, a proporçäo de células com aberraçöes cromossômicas estruturais manteve uma relaçäo aproximadamente crescente com o aumento da taxa de CBD


Subject(s)
Chromosome Aberrations , Cannabidiol/pharmacology , In Vitro Techniques , Lymphocytes/drug effects , Mitosis/drug effects
8.
Article in Portuguese | LILACS | ID: lil-141127

ABSTRACT

Comparou-se a acao do canabidiol, um dos derivados da Cannabis sativa, com diazepam e placebo, numa situacao dita geradora de ansiedade. Foram selecionados voluntarios com altos niveis de ansiedade-traco, avaliados atraves da parte I do Inventario de Ansiedade Traco-Estado (IDATE). Como Forma de inducao de ansiedade utilizaram-se dois testes: o "Mirror Drawing Test" (MDT) e ou "Stroop Color-Word Test" (SCWT). Compararam-se quatro grupos de voluntarios em esquema duplo-cego, os quais receberam uma unica dose de canabidiol (200 ou 300 mg) ou diazepam (5mg) ou placebo. Nao foram detectadas diferencas entre os quatro grupos no desempenho do SCWT. Sob acao do diazepam e 300mg de canabidiol houve uma diminuicao do desempenho no MDT. Na populacao estudada, o modelo utilizado nao se mostrou capaz de detectar a acao ansiolitica do diazepam e, eventualmente, do canabidiol. Sao discutidas as possiveis razoes desses resultados


Subject(s)
Humans , Anxiety/drug therapy , Cannabidiol/pharmacology , Diazepam/pharmacology , Double-Blind Method
SELECTION OF CITATIONS
SEARCH DETAIL